3
Indication details
- Combined Agent(s)
- Enzalutamide
- Control Arm
- Placebo plus enzalutamide
- Therapeutic Indication
- Talazoparib is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
- Tumour Type
-
Genitourinary Cancers
- Tumour Sub-type
- Prostate cancer
- Tumour Stage
- Metastatic castration-resistant
- Trial Name
- TALAPRO-2
- NCT Number
- NCT03395197
- Trial Phase
- Phase III
Approval details
- EMA Approval
- EMA (CHMP) November 2023. EC decision January 2024
- Comment
- The presented score is for the all-comers cohort (ITT)
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- PFS (ITT)
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 21.9 months
- PFS Gain
- 12.9 months
- PFS HR
- 0.63 (0.57-0.78)
Adjustments
- QoL Comment
-
QoL data pending
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 383
- Scorecard version
- 1
- Issue date
- 19.07.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.